Although the difference in the global methylomic profiles of these three classes may reflect their cell type composition, such as dominant epithelium component in LGMT DICER1, dominant sarcoma component in the other two classes and no epithelium in PIS DICER1, the identification of these DICER1-associated tumor classes from various anatomical sites will enable meaningful clinical trial stratification in the future and suggests that rational drug development addressing the differing molecular foundations of mesenchymal tumors with DICER1 alteration may be a plausible goal. Here, DICER1 is linked to sarcoma.